Concurrent Chemo-proton Therapy Using Adaptive Planning for Unresectable Stage III Non-small Cell Lung Cancer: A Phase II Study

Abstract Purpose This study prospectively evaluated the efficacy and safety of concurrent chemo-proton therapy (CCPT) using adaptive planning for unresectable stage III non-small cell lung cancer (NSCLC). Methods and Materials The primary endpoint was overall survival (OS). Secondary endpoints were local control rate (LCR), progression-free survival (PFS), incidence of grade 3 or higher adverse events, and changes in quality of life (QOL). Patients received cisplatin (60 mg/m2) on day 1 and S-1 (∼40 mg/m2 twice daily) on days 1-14, q4w, for up to 4 cycles, plus concurrent PT at a total dose of 70 GyRBE for the primary lesion and 66 GyRBE for lymph node metastasis with 2 GyRBE per day. PT was performed using respiratory-gated and image-guided techniques, and adaptive plans were implemented. Results Forty-seven patients were enrolled between August 2013 and August 2018. Four cycles of cisplatin plus S-1 were completed in 34 patients. The mean number of cycles was 4 (range: 1-4). The median follow-up period of all and surviving patients was 37 (range: 4-84) and 52 months (range: 26-84), respectively. The mean number of replanning sessions was 2.5 (range: 1-4). The 2- and 5-year OS, LCR and PFS were 77% (95% confidence interval: 64-89%) and 59% (43-76%), 84% (73-95%) and 61% (44-78%), and 43% (28-57%) and 37% (22-51%), respectively. The median OS was not reached. No grade 3 or higher radiation pneumonitis was observed. There was no significant deterioration in the QOL scores after 24 months except for alopecia. Conclusions CCPT with adaptive planning was well tolerated and yielded remarkable OS for unresectable stage III NSCLC.